Table 2.
Reports of c-MYC and BCL2 double-hit lymphomas of the thyroid gland
| Case | Age/sex | Histological type | Stage | International prognostic index | Treatment | Effect | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | 50/F | DLBCL | IV | LI | R-CHOP | CR → Relapse | Still alive after 19 Mo | This case |
| RX | ↓ | |||||||
| ↓ | CR | |||||||
| R-CHOP | ||||||||
| R-ESHAP | ||||||||
| MCVAC | ||||||||
| AUTO | ||||||||
| 2 | 54/F | NHL | N.A | N.A | Ara-C | N.A | DOD 29 Mo later | [8] |
| MTX | ||||||||
| 3 | 59/F | DLBCL | N.A | LI | R-CycloBEAP | N.A | Still alive after 9 Mo | [9] |
NHL non Hodgkin lymphoma; F female; LI low intermediate; R-CHOP rituximab, cyclophosphamide hydrate, doxorubicin hydrochloride, vincristine sulfate, prednisolone; RX radiation; R-ESHAP rituximab, etoposide, methylprednisolone sodium, cytarabine, cisplatin; MCVAC ranimustine, cytarabine, etoposide, cyclophosphamide; AUTO auto peripheral blood stem cell transplantation; Ara-C cytarabine; MTX methotrexate; R-CycloBEAP rituximab,cyclophosphamide,vincristine,bleomycin,etoposide,doxorubicin,prednisone; CR complete remission; Mo month; NA not available; DOD died of primary disease